Research programme: eosinophil-driven inflammatory disorder therapeutics - Alivexis
Alternative Names: Research programme: Anti-inflammatory therapeutics - AlivexisLatest Information Update: 16 Apr 2024
At a glance
- Originator Modulus Discovery
- Developer Alivexis
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Inflammation
Highest Development Phases
- Research Inflammation
Most Recent Events
- 24 Aug 2023 Eosinophili-driven inflammatory disorder therapeutics is available for licensing as of 24 Aug 2023. https://modulusdiscovery.com/pipeline/#partnering (Modulus Discovery pipeline, August 2023)
- 24 Aug 2023 Early research in Inflammation in Japan (unspecified route) prior to August 2023 (Modulus Discovery pipeline, August 2023)